1. Introduction {#sec1-ijms-19-04056}
===============

The Janus kinase (Jak) and Signal transducer and activator of transcription (STAT) signaling pathway is crucial in the regulation of the immune response, in stem cell regulation, and in determining cell identities in diverse organisms. In the late 1980s and early 1990s, this signaling cascade was shown to be central to the interferon response in humans (reviewed in \[[@B1-ijms-19-04056],[@B2-ijms-19-04056]\]), and its homologs were soon identified in *Drosophila* \[[@B3-ijms-19-04056],[@B4-ijms-19-04056],[@B5-ijms-19-04056],[@B6-ijms-19-04056],[@B7-ijms-19-04056]\]. The demonstration that activating mutations in Jak produced neoplastic growth in flies, particularly in blood cell-like lineages \[[@B8-ijms-19-04056],[@B9-ijms-19-04056],[@B10-ijms-19-04056],[@B11-ijms-19-04056]\], illustrated the striking similarity between the pathways across the animal kingdom, because, soon after, deregulated STAT function was linked to human hematopoietic malignancies and activating mutations in Jak were linked to leukemia and other myeloproliferative disorders \[[@B1-ijms-19-04056],[@B12-ijms-19-04056],[@B13-ijms-19-04056],[@B14-ijms-19-04056]\]. Given these parallels, it is no surprise that detailed characterization of the Jak/STAT pathway in *Drosophila* has been very informative about its functional mechanisms in humans.

Here, we broadly compare and contrast the Jak/STAT signaling cascade in mammals and *Drosophila*. We review studies linking key Jak/STAT activity regulators with human disease, especially blood cell cancer, cancer stem cells, and metastatic cancers derived from breast and prostate. We also describe well-characterized cell types and phenotypes affected by loss and gain of function of Jak/STAT pathway components in *Drosophila*, and discuss how flies can be useful for the identification of new pathway regulators. Finally, we explore connections between genes determined to be Jak/STAT regulators in *Drosophila* and their human homologs that are linked to disease, and highlight candidates for further study based on their involvement in both contexts.

2. Jak/STAT Signaling Overview in Flies and Humans {#sec2-ijms-19-04056}
==================================================

Extracellular cues trigger Jak/STAT signaling, which ultimately leads to transcriptional activation of target genes ([Figure 1](#ijms-19-04056-f001){ref-type="fig"}). The basic framework for this signaling is the same across species, but the mammalian signaling system includes families of proteins with overlapping roles, whereas the fly cascade has fewer components and less redundancy. In humans, a set of more than 40 interleukins and cytokines serve as activating cues (reviewed in \[[@B15-ijms-19-04056],[@B16-ijms-19-04056],[@B17-ijms-19-04056]\]). In flies, only three proteins hold this function: Unpaired (Upd) 1, Upd 2, and Upd 3 \[[@B4-ijms-19-04056],[@B18-ijms-19-04056],[@B19-ijms-19-04056],[@B20-ijms-19-04056]\]. Given the array of activators, mammals have multiple cell-surface receptors that can act singly or multimerize to respond to their diverse set of ligands \[[@B21-ijms-19-04056],[@B22-ijms-19-04056]\]. In contrast, one signaling receptor has been determined in flies, called Domeless (Dome) \[[@B5-ijms-19-04056],[@B6-ijms-19-04056],[@B23-ijms-19-04056],[@B24-ijms-19-04056]\], which can interact with the non-signaling receptor, Eye transformer (Et, similar to human type I receptor GP130) \[[@B25-ijms-19-04056],[@B26-ijms-19-04056],[@B27-ijms-19-04056]\]. Receptor--ligand binding activates Jak proteins docked to the cytoplasmic portion of the receptors. There are four Janus kinases in humans (Jak1--3 and Tyrosine kinase 2 (Tyk2)), which bind different receptors. One Jak protein is found in flies, which is most similar to human Jak 2. Like most *Drosophila* genes, the gene encoding Jak is named after its loss of function phenotype; due to defective segmentation and skipped segments in the cuticular patterns of late embryos and early larvae, the mutant was named *hopscotch* (*hop*, with similar phenotypes observed for *unpaired* mutants) \[[@B10-ijms-19-04056],[@B28-ijms-19-04056]\]. Janus kinases have a well-conserved structure, featuring a kinase domain, a similar pseudokinase domain without catalytic activity, and a band 4.1- ezrin-radixin-moesin (FERM) domain that binds to the receptor and contributes to the regulation of kinase activation upon receptor--ligand binding \[[@B29-ijms-19-04056]\]. Activated Jak targets a second Jak associated within the same receptor dimer or multimer, and the subsequent phosphorylations create binding sites for cytoplasmic STAT proteins. There exist seven STAT family members in humans (STAT1--4, 5a, 5b, and 6), but only one in flies: STAT92E, which is most similar to STAT5b \[[@B3-ijms-19-04056],[@B7-ijms-19-04056],[@B30-ijms-19-04056]\]. Conserved domains in STAT proteins include the coiled coil, Src Homology 2 (SH2), DNA binding, and transactivation domains \[[@B21-ijms-19-04056]\]. Non-phosphorylated STATs have been shown to have several functions in flies, including promoting heterochromatin formation with HP1 and maintaining genomic stability \[[@B31-ijms-19-04056],[@B32-ijms-19-04056],[@B33-ijms-19-04056]\]. Likewise, some STAT family members can function in mammalian cells without being phosphorylated, for example by interacting with cytoskeletal regulators, functioning at mitochondria or Golgi, modulating NF-κB signaling, increasing heterochromatin, or heterodimerizing with phosphorylated STATs \[[@B31-ijms-19-04056],[@B34-ijms-19-04056],[@B35-ijms-19-04056]\]. However, the best studied roles for the protein family are those that occur after it is \"activated\" by phosphorylation. Phosphorylated STATs dimerize, which promotes their translocation into the nucleus where they directly bind DNA and recruit transcriptional activators \[[@B21-ijms-19-04056]\]. Thus, the canonical Jak/STAT pathway results in changes in gene expression, including amplifying expression of its own regulators.

As the various STAT proteins in humans can homo- or hetero-dimerize, and can be activated by numerous permutations of the ligands, receptors, and Jaks, the combinatorial outcomes are very complex. Thus, the stripped-down pathway that exists in *Drosophila* is important to provide a tractable, but still very relevant, system for characterization of this signaling cascade and its essential regulators.

2.1. Requirement of Jak/STAT Signaling in Development and Adulthood {#sec2dot1-ijms-19-04056}
-------------------------------------------------------------------

In both flies and mammals, normal early development requires correct Jak/STAT signaling, and spatiotemporal pathway misregulation later in life is detrimental. Humans with inborn errors in Jak/STAT genes that are important in blood cell lineages are immunocompromised \[[@B36-ijms-19-04056]\]. Additionally, abnormally high Jak and STAT activities in adults have been closely associated with autoimmune diseases, cell overproliferation, acquisition of blood cell disorders, cancer progression, and poor cancer prognosis \[[@B14-ijms-19-04056],[@B15-ijms-19-04056],[@B37-ijms-19-04056],[@B38-ijms-19-04056],[@B39-ijms-19-04056]\]. In light of this, much research is directed at understanding this signaling pathway.

While some null Jak/STAT pathway mutations cause tissue-specific defects, presumably others would not allow human development to term, as evidenced by mouse genetic studies. Mutations in genes encoding positive signaling components result in early lethality in mice or cell type-specific effects \[[@B21-ijms-19-04056],[@B40-ijms-19-04056]\]. For example, mutant *Jak1* and *Jak3* mice have severe combined immunodeficiency (SCID), and *Jak1* mutants also have neurological defects and poor survival past birth; knock out mutations in *Jak2* are embryonic lethal, and mutations in the Jak family member *Tyk2* result in poor response to pathogens \[[@B29-ijms-19-04056]\]. Similarly, *Stat1* mutant mice have abnormal immune responses and are more susceptible to infections than wild type \[[@B40-ijms-19-04056]\], and show significant neurodegeneration as adults \[[@B41-ijms-19-04056]\]. *Stat3* mutant mice die in early embryogenesis and tissue-specific mutations result in changes in the proliferation--apoptosis balance in blood cells, poorer cell motility, and inflammation \[[@B21-ijms-19-04056],[@B40-ijms-19-04056]\]. *Stat5a* and *b* have overlapping, required roles in mammary gland and ovary development, as well as being important in blood cell proliferation and cytotoxic activity \[[@B40-ijms-19-04056],[@B42-ijms-19-04056]\]. Female *Stat5a/b* double knock out mice are sterile.

Mutations that block Jak/STAT signaling in *Drosophila* result in early lethality; however, this can be overcome experimentally using sophisticated genetic tools that allow fly researchers to test mutations in individual cell types or at certain times in development. These types of experiments can be performed by using temperature sensitive mutations, by tissue-specific expression control through the Gal4/UAS system, or by using clonal mosaic analysis, in which most cells of the organism are heterozygous and small clones of cells are homozygous mutant. (For reviews on methodology and Jak/STAT related genetic tools, see \[[@B43-ijms-19-04056],[@B44-ijms-19-04056]\]). These strategies revealed essential functions for Jak/STAT signaling in sex determination \[[@B45-ijms-19-04056],[@B46-ijms-19-04056],[@B47-ijms-19-04056],[@B48-ijms-19-04056]\], as well as in cellular functions in diverse cell types that include fly blood cells \[[@B49-ijms-19-04056],[@B50-ijms-19-04056]\], wing precursors \[[@B51-ijms-19-04056],[@B52-ijms-19-04056]\], eye progenitor cells \[[@B53-ijms-19-04056]\], gut stem cells \[[@B54-ijms-19-04056],[@B55-ijms-19-04056],[@B56-ijms-19-04056]\], adult testes stem cells \[[@B57-ijms-19-04056],[@B58-ijms-19-04056],[@B59-ijms-19-04056]\], and adult ovary cell types \[[@B23-ijms-19-04056],[@B24-ijms-19-04056],[@B60-ijms-19-04056],[@B61-ijms-19-04056]\] (see [Table 1](#ijms-19-04056-t001){ref-type="table"}). (For recent reviews on *Drosophila* Jak/STAT signaling in specific contexts, see \[[@B62-ijms-19-04056],[@B63-ijms-19-04056],[@B64-ijms-19-04056],[@B65-ijms-19-04056]\] (stem cells), \[[@B66-ijms-19-04056]\] (tumors), \[[@B49-ijms-19-04056],[@B50-ijms-19-04056],[@B67-ijms-19-04056]\] (hematopoiesis and immunity), \[[@B68-ijms-19-04056]\] (morphogenesis), \[[@B31-ijms-19-04056]\] (heterochromatin), \[[@B69-ijms-19-04056]\] (cell--cell competition), and \[[@B70-ijms-19-04056]\] (host--parasite interactions)). In many of these contexts, loss of signaling produced abnormal phenotypes, as did unusually high levels of signaling. We discuss several specific cases below. These experiments implicate Jak/STAT functional disruptions in defects in stem cell maintenance, cell survival, proliferative defects, cell fate specification, and cell migration in a variety of tissue types.

2.2. Jak/STAT Activity Regulators {#sec2dot2-ijms-19-04056}
---------------------------------

Given the many diverse roles for Jak/STAT signaling, and the fact that either too much or too little signaling can produce abnormal effects, it is not surprising that the pathway is subject to many levels of regulation. Estimates based on *Drosophila* cell culture screens suggest there are on the order of hundreds of regulators \[[@B71-ijms-19-04056],[@B72-ijms-19-04056],[@B73-ijms-19-04056]\].

Multiple regulatory proteins were initially discovered in mammalian contexts, then shown to play similar roles in flies. Among the first to be characterized was the family of proteins called Protein inhibitor of activated STAT (PIAS). These proteins bind to activated STATs to block DNA binding and transcriptional activity, and have roles in the sumoylation and downregulation and degradation of signaling components \[[@B74-ijms-19-04056],[@B75-ijms-19-04056],[@B76-ijms-19-04056],[@B77-ijms-19-04056]\]. There are seven mammalian PIAS proteins encoded by four genes, and each can differentially target STATs or affect other transcription factors. The single PIAS encoded in *Drosophila* inhibits STAT activity in blood cells and in the eye \[[@B78-ijms-19-04056]\]. Members of the suppressor of cytokine signaling (SOCS) pathway function as feedback inhibitors of STAT activity in mammals and flies \[[@B21-ijms-19-04056],[@B79-ijms-19-04056]\]. These can bind Jaks or the receptor directly through an SH2 domain and reduce kinase activity, which occurs through recruitment of proteins to promote ubiquitination and degradation \[[@B80-ijms-19-04056],[@B81-ijms-19-04056]\]. Eight SOCS proteins have been characterized in mammals; several of these have specific regulatory links to certain STATs, as well as roles in down-regulating other signaling pathways. Three SOCS proteins are encoded in flies but only two (Socs36E and Socs44A) are known to regulate Jak/Stat signaling \[[@B82-ijms-19-04056],[@B83-ijms-19-04056],[@B84-ijms-19-04056]\] and, in some contexts, these also modulate signaling through the epidermal growth factor receptor (EGFR), Ras, and Mitogen activated protein (MAP) kinases \[[@B85-ijms-19-04056],[@B86-ijms-19-04056]\]. When EGFR is activated, Socs36E functions as a tumor suppressor in epithelia and, similarly, depletion of SOCS5 function has a synergistic effect on cell transformation when combined with activation of EGFR or Ras/MAP kinase signaling in human cell culture \[[@B87-ijms-19-04056]\]. Fly Socs36E has an intrinsically disordered domain and can recruit upstream Jak/STAT pathway components to Cullin-dependent degradation \[[@B88-ijms-19-04056]\], similar to how it acts in human cells. In both flies and mammals, STAT transactivates *Socs* gene expression, creating feedback inhibition of the pathway \[[@B79-ijms-19-04056],[@B83-ijms-19-04056],[@B89-ijms-19-04056],[@B90-ijms-19-04056],[@B91-ijms-19-04056],[@B92-ijms-19-04056]\]. An additional well-characterized class of regulatory proteins is the protein tyrosine phosphatases (PTPs), which directly dephosphorylate Jaks and potentially STATs \[[@B71-ijms-19-04056],[@B93-ijms-19-04056],[@B94-ijms-19-04056]\], reversing their activation. This is a very large family in mammals with cell type-specific expression; multiple members have been shown to function in Jak/STAT signaling, especially in cell type-specific ways \[[@B95-ijms-19-04056]\]. So far, one member of this family, Ptp61F, is linked to Jak/STAT signaling in *Drosophila* \[[@B71-ijms-19-04056],[@B73-ijms-19-04056],[@B96-ijms-19-04056]\]. Another negative regulator is the transmembrane receptor, Et, which, although it is structurally similar to mammalian GP130, acts as an inhibitory receptor by interacting with Dome and blocking its homo-dimerization and activation \[[@B25-ijms-19-04056],[@B26-ijms-19-04056],[@B27-ijms-19-04056]\]. Finally, regulation of receptor internalization via endocytosis is a regulatory mechanism common across species that modulates Jak/STAT signaling \[[@B97-ijms-19-04056],[@B98-ijms-19-04056],[@B99-ijms-19-04056],[@B100-ijms-19-04056],[@B101-ijms-19-04056],[@B102-ijms-19-04056]\].

More recently, flies have been used to identify novel regulators of Jak/STAT signaling. This has been accomplished by identifying mutants with similar phenotypes, by leveraging unbiased genetic enhancement and suppression screening, and by assaying pathway activity in cell culture. Many of the proteins identified in this way have human homologs that may play analogous roles. Given that Jak/STAT activity has important functions in immune response, cell motility, and stem cell maintenance in both humans and flies, genetic analysis in the fly provides a valuable strategy to elucidate critical regulators in these processes. Thus, studying different cellular contexts and using multiple approaches will be useful for determining how these components are controlled and how they normally fine-tune the pathway to prevent pathological states. We will describe Jak/STAT regulation in three contexts: Mammalian blood cell differentiation and proliferation, stem cell signaling, and cell motility and metastasis. Next, we will draw parallels with regulation of these processes in flies via Jak/STAT signaling. Finally, we will explore the potential contributions for homologs of *Drosophila* Jak/STAT regulators in metastasis.

3. Jak/STAT Signaling in Blood Cell Proliferation and Cell Fate {#sec3-ijms-19-04056}
===============================================================

3.1. Jak/STAT Signaling and Human Blood Cell Development and Disease {#sec3dot1-ijms-19-04056}
--------------------------------------------------------------------

In humans, blood cells are produced from hematopoietic stem cells (HSC), which reside in a stem cell niche in bone marrow. HSCs divide asymmetrically to renew and make multipotent daughter cells; depending on local factors, these will produce multipotent stem cells restricted either to lymphoid or myeloid lineages. Jak/STAT signaling is important in both stem cell regulation and differentiation. STAT5 is expressed in HSCs and is necessary for their ability to self-renew \[[@B39-ijms-19-04056],[@B103-ijms-19-04056]\], and STAT3 is also active in HSCs but is not strictly required \[[@B104-ijms-19-04056]\]. Mouse knock out experiments demonstrate that both STAT3 and STAT5 are needed for B-cell development, and STAT5 is necessary for differentiation of some myeloid cell types \[[@B39-ijms-19-04056]\].

Multiple different mutations in the human Jak/STAT signaling pathway or its positive regulators result in a defective immune response or proliferative disorders in blood cells \[[@B14-ijms-19-04056],[@B21-ijms-19-04056],[@B37-ijms-19-04056],[@B39-ijms-19-04056]\]. Loss of function mutations are linked to immune diseases and the inability to fight certain kinds of infections \[[@B14-ijms-19-04056],[@B36-ijms-19-04056]\]. Conversely, aberrantly high Jak/STAT signaling is well-known for promoting myeloproliferative disorders, including leukemia and lymphoma \[[@B14-ijms-19-04056],[@B39-ijms-19-04056]\]. In these diseases, extra cell division and poor differentiation of certain white blood cell types in bone marrow renders the immune system dysfunctional and causes overproliferation and tumors. Genetic fusions between Jak2 and the Translocation-Ets-leukemia (Tel/ETV6) gene that constitutively activate Jak appear to be causative for some cases of chronic myeloid leukemias and acute lymphoblastic leukemia. Other hematopoietic malignancies show activation of Jak1 or Jak3 through different means \[[@B14-ijms-19-04056],[@B39-ijms-19-04056]\]. A rare chronic leukemia called myelofibrosis is most commonly caused by activating mutations in Jak2 \[[@B105-ijms-19-04056]\]. This blood cell disorder alters stem cell dynamics in bone marrow and results in scarring or fibrosis of the bone marrow, disrupting the stem cell niche. Similarly, polycythemia vera is a rare neoplastic blood disorder often caused by activating mutations in Jak2 that result in the overproduction of red blood cells \[[@B106-ijms-19-04056]\]. Transformation of blood cells by oncogenes often results in aberrant activation of STAT1, 3, or 5, depending on the originating cell type, and this can occur independently from canonical upstream signaling \[[@B14-ijms-19-04056],[@B39-ijms-19-04056]\]. This activation can promote proliferation, differentiation defects, and stem cell-like character or neoplasia.

Since activating mutations lead to disease, several drugs are currently used therapeutically to suppress Jak/STAT signaling in patients. AG490 was the first Jak inhibitor characterized, and it has been used in the treatment of acute lymphoblastic leukemia; other drug analogs have been shown to be effective in blocking acute myeloid leukemia progression and survival in cell culture \[[@B14-ijms-19-04056],[@B39-ijms-19-04056],[@B107-ijms-19-04056],[@B108-ijms-19-04056]\]. A Jak1/2 inhibitor, ruxolitinib (Jakifi), is the only therapeutic agent for the treatment of myelofibrosis in the US. Tofacitinib (Xeljanz), a pan-Jak inhibitor, modulates the immune response via Jak1/3 and STAT1 \[[@B109-ijms-19-04056]\], and is approved in the US for treatment of inflammatory arthritis and rheumatoid arthritis. The Jak inhibitor, ADZ1480, has been found to be effective in blocking the growth and survival of cell lines derived from multiple different solid tumors and carcinomas \[[@B39-ijms-19-04056]\]. While these drugs are promising and more clinical trials are underway, many have significant side effects, indicating that better drugs are needed.

3.2. Drosophila Hemocytes as a Model for Blood Disorders {#sec3dot2-ijms-19-04056}
--------------------------------------------------------

*Drosophila* hemocytes show many similarities to human white blood cells and play critical roles in the immune response. The fly innate immune system acts through the production of antimicrobial peptides and the phagocytosis of pathogens. *Drosophila* have an open circulatory system and do not require oxygenated red blood cells. However, three types of blood cells differentiate from hemocytes: Plasmatocytes, which phagocytose bacteria and are most similar to human macrophages; crystal cells, which are responsible for melanization of pathogens; and lamellocytes, which encapsulate large foreign invaders like wasp eggs \[[@B67-ijms-19-04056],[@B70-ijms-19-04056],[@B110-ijms-19-04056]\]. The main hematopoietic stem cells reside in the larval lymph gland. The posterior signaling center of the lymph gland produces Upd family members, which induces Jak/STAT signaling in hemocyte progenitors, maintaining the stem-like character and preventing them from differentiating too soon \[[@B49-ijms-19-04056],[@B111-ijms-19-04056]\]. An interesting, recent study showed that proper blood cell differentiation decisions in the lymph gland depend on signaling from embryonic hemocytes \[[@B112-ijms-19-04056]\]. Hemocytes express the transcription factor Glial cells missing (Gcm), which is required to activate Jak/STAT negative regulators and prevent the pro-inflammatory effects of overactivation Upd 2 and Upd 3 expression or infection. This indicates that initial waves of signaling control have repercussions much later in development.

Like in mammals, Jak/STAT interacts with multiple signaling pathways in the hematopoietic compartment to control hemocyte differentiation and proliferation. Interactors include the combined homolog of platelet-derived growth factor and vascular endothelial growth factor, PVF2 \[[@B113-ijms-19-04056],[@B114-ijms-19-04056]\]; the Hippo pathway transcription factor, Yorkie \[[@B115-ijms-19-04056]\]; the homolog of early B-cell factor, Collier \[[@B111-ijms-19-04056]\]; and the GATA factors, U-shaped and Pannier, which promote prohemocytes and differentiation, respectively \[[@B116-ijms-19-04056],[@B117-ijms-19-04056],[@B118-ijms-19-04056]\]. The Jak/STAT signaling regulator, Asrij, is expressed in blood cells and other cell types, suggesting it is important in differentiation as well \[[@B119-ijms-19-04056]\], and it regulates endocytic turnover of signaling components \[[@B120-ijms-19-04056]\]. Interestingly, many of the transcriptional targets of STAT are conserved between fly hemocyte-derived tumors and HeLa cells \[[@B121-ijms-19-04056]\], again supporting the idea that the signaling pathway is similar. Recent work indicates that quiescent hemocyte stem cells reside in adult flies, in addition to larval lymph glands, and are activated in response to infection \[[@B122-ijms-19-04056]\], but the effects of Jak/STAT signaling on this have not yet been revealed. However, since Jak/STAT signaling is activated upon immune challenge in *Drosophila*, the pathway is necessary for an effective immune response in larva and adults \[[@B49-ijms-19-04056],[@B50-ijms-19-04056],[@B67-ijms-19-04056],[@B123-ijms-19-04056],[@B124-ijms-19-04056]\].

A dominant, activating mutation in *Drosophila* Jak, Hop^Tumorous-lethal^ (Hop^Tum^), has provided an invaluable tool in the study of Jak/STAT signaling in flies \[[@B10-ijms-19-04056]\]. This point mutation creates a single glycine to glutamic acid change in the pseudokinase domain, which renders the catalytic domain constitutively active \[[@B8-ijms-19-04056],[@B9-ijms-19-04056],[@B10-ijms-19-04056],[@B11-ijms-19-04056]\]. Mutants die in larval stages with dark, neoplastic tumors of a melanotic blood cell subtype, reminiscent of human leukemia \[[@B125-ijms-19-04056]\]. A different point mutation, Hop^T42^, creates an activating amino acid substitution in the kinase-like domain, which results in phenotypes similar to those due to Hop^Tum^ expression \[[@B9-ijms-19-04056]\]. When this conserved amino acid is substituted in mouse Jak2, the mammalian protein, likewise, is constitutively activated. Interestingly, expression of a causative fusion protein in acute myeloid leukemia, Runt-related transcription factor 1(Runx1/AML1)-ETO, also caused expansion of hemocyte precursors \[[@B126-ijms-19-04056]\], supporting the idea that *Drosophila* hemocytes provide a reasonable model for leukemia mechanisms.

A number of drug screens for Jak/STAT inhibitors have been performed using a cultured cell line derived from *Drosophila* embryonic hemocytes \[[@B127-ijms-19-04056],[@B128-ijms-19-04056],[@B129-ijms-19-04056],[@B130-ijms-19-04056]\]. Notably, drugs suppressing Jak activity in humans also work against the fly counterpart, indicating functional and structural conservation across species. For example, the commonly-used drug, ruxolitinib, inhibits Jak/STAT signaling in fly cell culture \[[@B130-ijms-19-04056]\]. Notably, this line of work showed that methotrexate specifically inhibits Jak/STAT signaling as well as ruxolitinib does \[[@B129-ijms-19-04056]\]. Transferring this finding to cultured Hodgkin lymphoma cells, the study showed that methotrexate can suppress signaling even in the presence of the V617F activating mutation in Jak. Additionally, a novel compound, MS1040, was identified as a specific Jak inhibitor in fly cells and mammals \[[@B131-ijms-19-04056]\], which could have clinical relevance. In another interesting line of work, approved chemotherapeutic agents for humans were administered to flies bearing a genetically-induced intestinal stem cell tumor \[[@B132-ijms-19-04056]\]. Although some drugs could reduce the tumors, one class additionally caused overproliferation of normal stem cells. This effect was mediated via Jak/STAT activation, and may reveal clues to the biology of tumor recurrence in humans. Since combination therapy is a strong direction for future treatments of myeloproliferative disorders and cancers broadly, more work to identify specific and effective drugs is needed, and Jaks are a good target. These studies illustrate the utility of drug screening in *Drosophila*.

4. Jak/STAT Regulation of Stem Cell Character {#sec4-ijms-19-04056}
=============================================

4.1. Jak/STAT Signaling, Carcinomas, and Cancer Stem Cells {#sec4dot1-ijms-19-04056}
----------------------------------------------------------

Besides its involvement in blood cell cancers, Jak/STAT signaling activation is common in carcinomas. Activated STAT3 and STAT5, in particular, promote tumorigenesis and cancer stem cells, and this has been extensively reviewed \[[@B15-ijms-19-04056],[@B21-ijms-19-04056],[@B133-ijms-19-04056],[@B134-ijms-19-04056],[@B135-ijms-19-04056],[@B136-ijms-19-04056]\]. Cancer stem cells are rare, but can proliferate and are believed to contribute to resistance to treatment and cancer recurrence. STAT activity inhibition slows cancer cell growth and may change stem-like character; therefore, drugs to block the pathway, like ADZ1480, are being heavily investigated. One model posits that the cancer recurrence common with STAT-positive cancers is due to the ability of STAT to provide signals that induce niche-like properties, maintaining cancer stem cells non-autonomously \[[@B135-ijms-19-04056]\]. As with hematopoietic stem cells, cancer stem cells are subject to many regulatory factors that impact the decisions to self-renew or differentiate. Since these stem cells are rare and usually hard to identify, it is helpful to examine stem cell regulation in other contexts. Research of *Drosophila* has provided strong insight into the molecular regulation of stem cells and the niches that support them.

4.2. Drosophila Testes Stem Cells {#sec4dot2-ijms-19-04056}
---------------------------------

The *Drosophila* testis is an outstanding model for examining stem cell regulation, as it is well-characterized, clearly organized, and genetically accessible. Adult testes have two stem cell populations, the germline cells and the somatic cyst stem cells \[[@B65-ijms-19-04056],[@B137-ijms-19-04056]\]. Distal hub cells and cyst stem cells both act as a stem cell niche for the germline stem cells to maintain pluripotency. As cells divide and move away from the niche, they begin to differentiate. Thus, the testis provides a well-suited context to study how different signals act to influence the balance of stem cells. As in blood cells, gain or loss of Jak/STAT signaling in testes results in dramatic phenotypes, disrupting stem cell regulation and proliferative control. In this case, low STAT activity leads to a loss of somatic stem cells, which in turn causes germ line stem cell loss due to differentiation \[[@B57-ijms-19-04056],[@B58-ijms-19-04056],[@B59-ijms-19-04056],[@B138-ijms-19-04056],[@B139-ijms-19-04056]\]. Conversely, somatic overactivation of the pathway leads to excessive cyst stem cells, which expands the stem cell niche and leads to the production of higher numbers of germline stem cells. In somatic stem cells, the transcription factor, Zinc finger homeodomain 1 (Zfh1), is the key effector of Jak/STAT signaling, and it itself is necessary and sufficient to promote stem cell fate \[[@B57-ijms-19-04056],[@B140-ijms-19-04056]\]. The Jak/STAT negative regulators, Ptp61F and Socs36E, are important in this tissue as well \[[@B85-ijms-19-04056],[@B138-ijms-19-04056],[@B139-ijms-19-04056],[@B141-ijms-19-04056]\]. Higher Ptp61F resulted in more differentiated cells \[[@B141-ijms-19-04056]\]. Loss of *Socs36E* led to excessive signaling, overproliferation of stem cells, and changes in stem cell adherence to the niche \[[@B139-ijms-19-04056]\], which enables mutant cells to outcompete wild type neighbors \[[@B85-ijms-19-04056]\]. While these phenotypes are due in part to changes in Jak/STAT signaling, these regulators also have other targets. For example, high Socs36E in testes downregulated MAP kinase signaling in addition to Jak/STAT activity \[[@B85-ijms-19-04056]\].

Key transcription factors and epigenetic regulators have been found to impact the output of Jak/STAT activity in testes, and provide feedback on signaling to prevent it from getting too high or too low. The B-cell lymphoma Bcl6 homolog, Ken and Barbie (Ken), is needed in the somatic stem cells to repress the Jak/STAT inhibitor Ptp61F; thus, Ken indirectly maintains high enough levels of Jak/STAT activity for stem cell self-renewal \[[@B141-ijms-19-04056]\]. Ken opposes STAT activity by repressing some STAT target genes. The positive STAT regulator nucleosome-remodeling factor (NURF) acts to promote Jak/STAT-mediated stem cell maintenance and prevents differentiation \[[@B142-ijms-19-04056]\]. Conversely, the enhancer of polycomb, a part of a histone acetyltransferase complex \[[@B143-ijms-19-04056],[@B144-ijms-19-04056]\], and the ubiquitously transcribed tetratricopeptide repeat gene on the X chromosome (dUTX), a histone demethylase \[[@B145-ijms-19-04056]\], both increase *Socs36E* expression and downregulate STAT activity. These function to counteract Jak/STAT signaling and promote somatic cell differentiation instead of stem cell maintenance. Similarly, the transcription factor, Apontic, suppresses Jak/STAT signaling to limit the number of somatic stem cells and thus limit the size of the stem cell niche, also by promoting expression of *Socs36E* and probably a STAT-directed microRNA \[[@B146-ijms-19-04056],[@B147-ijms-19-04056]\]. These results implicate chromatin regulation in STAT target gene expression, and illustrate the tight regulation required on the pathway to make the amount of signaling optimal.

5. Jak/STAT Signaling Promotes Cell Motility and Metastasis {#sec5-ijms-19-04056}
===========================================================

Jak/STAT signaling activation has been linked to more metastatic cancers for a number of tumor types ([Table 1](#ijms-19-04056-t001){ref-type="table"}). A number of lines of evidence support this idea, from higher levels of signal detected in human metastases to xenograph and cell culture assays, which show that carcinoma cells are more invasive or motile in response to higher Jak/STAT activity, especially that of STAT3 and STAT5 \[[@B14-ijms-19-04056],[@B21-ijms-19-04056],[@B37-ijms-19-04056],[@B39-ijms-19-04056]\]. To draw comparisons to the fly model, we will focus on two well-studied cases, breast and prostate cancers, below. We focus our discussion to recent results linking Jak/STAT signaling to the acquisition of cell motility. It is worth noting that metastatic disease can also be promoted by immune system activation, which can be Jak/STAT dependent, but we will concentrate on cell-autonomous means of promoting motility. We go on to describe how Jak/STAT signaling and its regulation is critical in the proper determination of a motile cell type in *Drosophila*---the border cells ---and we outline how border cell behaviors capture aspects of metastatic cell migration.

5.1. Jak/STAT Signaling in Breast Cancer Metastasis {#sec5dot1-ijms-19-04056}
---------------------------------------------------

About 80% of diagnosed breast cancers are invasive, which threatens advancement to metastatic disease \[[@B148-ijms-19-04056]\]. Metastatic cancer is much more likely to be lethal than carcinoma in situ. Jak/STAT signaling is a key regulator of cell migration and proliferation in this context \[[@B14-ijms-19-04056],[@B21-ijms-19-04056],[@B37-ijms-19-04056],[@B39-ijms-19-04056]\]. In particular, Jak2-STAT5b signaling is often over-activated during tumor cell proliferation and metastatic spread of breast cancer. An analysis of multiple breast cancer cell lines showed that STAT5b is often constitutively phosphorylated at Y699 and activated \[[@B149-ijms-19-04056]\]. Invasion into Matrigel is commonly used to assess a cell type's metastatic potential. STAT5b silencing significantly inhibited invasion of a metastatic breast cancer cell line (T47D), compared to controls. Further studies showed that combinational drug therapy targeting Jak2-STAT5b signaling inhibited breast cancer metastasis \[[@B150-ijms-19-04056]\]. Drug treatment downregulated STAT5b nuclear localization, binding activity, and downstream target gene expression. Downregulation of Jak2-STAT3 by overexpression of WW domain-containing oxidoreductase (Wwox), which inhibits Jak2 phosphorylation, attenuated cell migration in vitro and suppressed metastasis in vivo \[[@B151-ijms-19-04056]\]. These data suggest Jak2-STAT5b significantly participate in promoting metastasis. A particularly hard-to-treat subtype of breast cancer is triple-negative breast cancer (TNBC), which lacks the human epidermal growth factor receptor 2 (HER2) and hormone receptors for estrogen and progesterone \[[@B152-ijms-19-04056]\]. Jak2 is often amplified in TNBC cell lines and specific inhibition of Jak2-STAT5 signaling with the drug ruxolitinib reduced proliferation of cells in culture, as well as tumor growth in vivo \[[@B153-ijms-19-04056]\], suggesting this is a good avenue for developing treatment regimes. Upstream of Jak2 and STAT3, IL6 is also linked to breast cancer metastasis: IL6 expression was found to be higher at the invasive leading edge of human primary breast cancer cells \[[@B154-ijms-19-04056]\]. Overexpression of IL6 signaling induced metastasis and tumor growth in mouse models, while its downregulation suppressed growth and reduced metastatic progression. Thus, the core components of canonical Jak/STAT signaling seem to be integral in mediating cell proliferation and metastatic disease.

Layered over the core signaling, conserved regulators of Jak/STAT signaling also impact human breast cancer metastasis, although not always as expected. Given the key role of Jak2, it is clear that regulators mediating its degradation have a critical function in preventing overactivation. SOCS protein family members are known for their negative regulation of Jak/STAT signaling \[[@B81-ijms-19-04056],[@B155-ijms-19-04056]\]. SOCS1 is overexpressed in TNBC tissues and cell lines \[[@B156-ijms-19-04056]\]. SOCS1 is significantly associated with distant metastasis and its downregulation suppressed the proliferation of TNBC. Overexpression of SOCS1 protein correlates with lymph node metastasis, large tumor size, and advanced clinical stages in TNBC patients, but it is not likely to be targeting Jak/STAT in this case. In contrast, SOCS3 promotes ubiquitination of Jak2 to reduce its expression and regulate cytokine signaling, whereas tropomyosin-related kinase C (TrkC) prevents the SOCS3-mediated ubiquitination of Jak2 \[[@B157-ijms-19-04056]\]. TrkC first binds and interacts with the c-Src/Jak2 complex to increase Jak2 and STAT3 levels, which induces Twist 1 and 2 expression. Carcinomas that become metastatic are thought to undergo an epithelial--mesenchymal transition (EMT), in which they lose apical basal polarity, reduce E-cadherin-based adhesions, and adopt the characteristics of migratory, loosely-connected mesenchymal cells. Twist 1 and 2 are known to be EMT-promoting transcription factors that may elevate metastatic potential.

Additional conserved regulators are relevant to breast cancer, although direct modulation of Jak/STAT activity has not been defined in all cases. The transcriptional repressor, BCL6, appears to be important to promote mesenchymal properties of breast cancer cells \[[@B158-ijms-19-04056]\]. E-cadherin is often downregulated during cell invasion to allow detachment from the tumor, and BCL6 serves a transcriptional repressor of *E-cadherin* in breast cancer cells. In breast metastatic lesions, reduction of activated nuclear STAT5a levels correlated to increased BCL-6 cellular expression \[[@B159-ijms-19-04056]\]. PTP1B is also involved in breast cancers, acting as an antiproliferative agent. PTP1B acts a negative regulator of both STAT5 and Jak2 activation in invasive breast cancer cell lines \[[@B160-ijms-19-04056]\]. Breast cancer patients with distant metastases showed high levels of PTP1B protein \[[@B161-ijms-19-04056]\]. Lastly, PIAS has not yet been shown to be a direct Jak/STAT signaling regulator in human breast cancer metastasis, but it is involved in the disease. Inhibition of the ligase activity of PIAS1 increased metastases to bone in mice after injection of human breast cancer cells \[[@B162-ijms-19-04056]\]. Further investigation of these regulators of Jak/STAT signaling and of the pathway itself may shed more light on the intricate molecular mechanisms of breast cancer metastasis.

5.2. Jak/STAT Signaling in Prostate Cancer Metastasis {#sec5dot2-ijms-19-04056}
-----------------------------------------------------

As with other carcinomas, Jak/STAT core components, IL-6, Jak2, and STAT5, and other key regulators of this pathway are implicated in promotion of prostate tumor growth and metastasis, and there is no highly effective treatment to cure metastatic disease. Activated STAT5a/b indicates a poor prognosis \[[@B163-ijms-19-04056]\]. Abnormal STAT5 activation was detected in over 60% of distant prostate cancer metastasis, including over 80% of those in lymph nodes in human clinical samples \[[@B164-ijms-19-04056]\]. Moreover, two human prostate cancer cell lines with metastatic potential (DU145 and PC-3) displayed a three-fold increase in cell migration in wound healing assays upon STAT5 activation. When DU145 cells expressing activated STAT5 were injected into mice, it resulted in eleven times more lung metastases compared to control injections without activated STAT. This indicates that STAT activation can drive metastasis. However, this mechanism might be dependent on Src kinases instead of Jak. STAT5 has been shown to interact with the androgen receptor, via its DNA binding domain, and protect it against proteosomal degradation, which can induce tumor growth in prostate cancer cells and may not require Jak \[[@B163-ijms-19-04056]\]. The IL-6 receptor has also been shown to promote prostate cancer metastasis. Soluble IL-6 binds to gp130, which activates it, but the inhibition of this factor reduced cell migration of DU145 cells in scratch assays and, conversely, the increased soluble IL-6R expression in DU145 cells reduced their adhesion by 25% \[[@B165-ijms-19-04056]\]. IL-6 also downregulated the Maspin tumor suppressor in prostate cancer cell lines.

Further evidence for activated Jak2-STAT5a/b signaling leading to metastasis comes from the findings that this pathway regulates EMT markers \[[@B166-ijms-19-04056]\]. The activated signaling induced mesenchymal markers, including the transcription factor, Twist, and the stem cell factor, BMI1, a polycomb group repressor component, and repressed epithelial markers, including E-cadherin in human prostate cell lines, xenograft mouse models, and patient derived explant cultures. Interestingly, reduction of Twist suppressed the activated STAT pro-migration effects. STAT5 activation also prompted significant reduction of E-cadherin expression in xenographs using a cell line that normally has high levels of this adhesion molecule. The in vivo inoculation of DU145 prostate cancer cells with Jak2-STAT5a/b, activated through the expression of prolactin, increased tumor metastasis by 69% in mice. Additionally, inhibition of Jak2 with the drug AZD1480 blocked Jak2-STAT5a/b signaling and suppressed prostate tumor growth in both cell culture and mouse models \[[@B167-ijms-19-04056]\]. Additional human Jak and STAT homologs, with partial similarity to Hop and STAT92E, also have implications in prostate cancer \[[@B168-ijms-19-04056]\], which are not discussed here. Thus, clearly the IL6-Jak2-STAT5 axis plays a regulatory role in prostate cancer and metastasis.

Disruptions of key, conserved regulators of Jak/STAT signaling are also implicated in human prostate cancer. The SOCS family appears to be involved. SOCS1 caused significant reductions in wound closure and invasive behavior when it is stably expressed in prostate cancer cell lines \[[@B169-ijms-19-04056]\]. In mouse models having metastatic tumors, none of the SOCS1-expressing mice had macro metastasis, unlike the controls, suggesting a role for SOCS1 in metastasis suppression. SOCS1 expression was significantly reduced in patients with metastatic prostate cancer, likely due to overexpression of a regulatory microRNA. SOCS1 likely acts on the MET and hepatocyte growth factor receptor tyrosine kinase, but may have other roles. These data make SOCS1 a strong candidate to be investigated as a Jak/STAT regulator in this context. GP130, a receptor subunit of IL-6, increased the invasiveness of prostate cancer cells and reduced E-cadherin levels in vitro \[[@B170-ijms-19-04056]\]. Patients with aggressive prostate cancer had elevated levels of soluble GP130. Thus, GP130 might exert upregulation of Jak/STAT signaling to contribute to prostate cancer metastasis and proliferation.

Other typical Jak/STAT regulators may function differently than expected in prostate cancer. Although PTP1B inhibits STAT activity, other PTPs seem to promote tumorigenesis or metastasis. PTP1B is overexpressed at the protein level in clinical samples of prostate tumors \[[@B171-ijms-19-04056]\]. The copy number of the gene encoding PTP1B was also increased by more than 20% in metastatic tumor samples. PTP1B silencing did not highly affect cell proliferation; however, it drastically impaired the migration and invasive properties of tumor cells in culture. These results suggest PTP1B functions independently from conventional Jak/STAT inhibition in prostate cancer metastasis. PIAS1 is another protein expected to reduce Jak/STAT activity. Elevated PIAS1 protein expression has been observed in primary tumors and metastatic lesions from prostate cancer patients \[[@B172-ijms-19-04056]\]. PIAS1 expression increased further after chemotherapy in resistant cells. Short term inhibition of PIAS1 resulted in reduced cell proliferation, while long-term inhibition triggered apoptosis in vitro. Thus, like PTP1B, PIAS1 seems to have roles independent from suppressing proliferative Jak/STAT signaling. Although confirmation is needed to determine these mechanisms, it is interesting that multiple Jak/STAT signaling regulators are implicated in prostate cancer metastasis, even if they work through different modes of action.

5.3. Jak/STAT Promotes Border Cell Migration in the Ovary {#sec5dot3-ijms-19-04056}
---------------------------------------------------------

The first evidence for Jak/STAT signaling promoting cell motility came from *Drosophila* border cells, a subset of somatic follicular cells in the adult ovary \[[@B23-ijms-19-04056],[@B24-ijms-19-04056],[@B60-ijms-19-04056]\]. Egg chambers in the ovary, which will each give rise to one egg, develop as a set of germline cells surrounded by a somatic monolayer epithelium of follicle cells. (For general fly oogenesis patterning reviews, see \[[@B173-ijms-19-04056],[@B174-ijms-19-04056]\]). At each pole of the developing egg chamber, polar cells form, which secrete Upd 1 and Upd 3 \[[@B4-ijms-19-04056],[@B19-ijms-19-04056],[@B175-ijms-19-04056]\]. Early STAT signaling is critical in this population for regulating apoptosis and permitting the survival of two polar cells \[[@B176-ijms-19-04056]\]. Secreted Upd acts as a morphogen to pattern the follicular epithelium \[[@B177-ijms-19-04056],[@B178-ijms-19-04056]\]. In response to Upd, about 12 nearby cells activate STAT signaling, and approximately six maintain high levels of activation and become the motile border cells \[[@B23-ijms-19-04056],[@B24-ijms-19-04056],[@B175-ijms-19-04056],[@B178-ijms-19-04056]\]. At a key time in egg development, these cells become motile, surround the non-motile polar cells, invade into the adjacent germline tissue, then migrate as a group to the oocyte, where they are required for patterning and egg structure. This chemotactic migration integrates signals from multiple signaling pathways, including EGF and PDGF/VEGF \[[@B179-ijms-19-04056]\]. In addition to Jak/STAT's requirement in the acquisition of border cell motility, the cell cluster's continued migration relies on STAT activity \[[@B61-ijms-19-04056]\]. A key effector of this migratory fate decision is the transcription factor Slow border cells (Slbo), a homolog of human CCAAT Enhancer Binding Protein Delta (CEBPD). Interestingly, not only is STAT activation necessary for cell migration, but it is sufficient among epithelial cells in the egg chamber to induce motility \[[@B24-ijms-19-04056],[@B60-ijms-19-04056]\]. Ectopic or continuous overactivation of the pathway results in too many cells becoming migratory. Thus, the ovary provides an ideal context for identification of Jak/STAT pathway regulators of cell motility, and the border cells are an outstanding model system for investigating genes that promote migration, which include many that are activated in metastasis \[[@B180-ijms-19-04056],[@B181-ijms-19-04056],[@B182-ijms-19-04056]\].

Border cell motility has been likened to an EMT event; however, border cells move as a collective that retain some epithelial character. In particular, apical--basal polarity components are required \[[@B183-ijms-19-04056],[@B184-ijms-19-04056],[@B185-ijms-19-04056]\]. Additionally, while downregulation of E-cadherin is known as a classic marker of EMT, in border cells it must be maintained. E-cadherin is an important downstream target activated by STAT and Slbo in border cells. E-cadherin is highly concentrated, subcellularly, toward the center of the cluster, and it is required there to maintain cluster integrity \[[@B186-ijms-19-04056],[@B187-ijms-19-04056]\], and probably to maintain association between the Upd-secreting polar cells and the motile border cells to maintain STAT pathway signaling. At the outer edges of the cells, E-cadherin is needed for traction to move over germline cells, but its protein level is lower, presumably due to cell adhesions being continuously remodeled. Some current studies suggest carcinomas may metastasize as mixed cell clusters similar to border cells \[[@B182-ijms-19-04056],[@B188-ijms-19-04056],[@B189-ijms-19-04056],[@B190-ijms-19-04056],[@B191-ijms-19-04056]\].

Since high levels of Jak/STAT signaling results in additional motile border cells, loss of function mutations in negative regulators also yield this phenotype. Mutations in *Socs36E*, a Socs5 homolog, or protein tyrosine phosphatase, *Ptp61F*, a homolog of the human gene encoding PTP1B, both disrupt border cell migration by allowing too many cells to become motile, due to excessive Jak/STAT signaling \[[@B61-ijms-19-04056],[@B89-ijms-19-04056],[@B96-ijms-19-04056]\]. Interestingly, *Socs36E* transcription is activated in response to STAT activity, functioning as an autoregulatory break on the signaling system \[[@B89-ijms-19-04056]\]. Ptp61F is thought to reduce Jak/STAT signaling by dephosphorylation of the receptor or Jak, or both, which is also the case for the mammalian PTPs \[[@B71-ijms-19-04056],[@B96-ijms-19-04056]\].

A number of additional Jak/STAT regulators involved in border cell migration have been identified through unbiased genetic screens and further characterized. In particular, numerous transcriptional regulators influence pathway output. The Bcl6 homolog Ken functions to promote sufficiently high Jak/STAT activity levels by transcriptionally suppressing a *Stat92E*-targeted microRNA, *mir-279* \[[@B192-ijms-19-04056]\]. While a homologous microRNA has not been identified in humans, other microRNA regulators exist that target signaling components \[[@B135-ijms-19-04056]\]. An additional transcription factor in this regulatory network in border cells is the Jak/STAT feedback inhibitor, Apontic, but the closest human homolog for this protein, the fibrinogen silencer binding protein, is not very well studied \[[@B178-ijms-19-04056]\]. Apontic is activated by the Eyes absent (EYA) transcriptional factor, and promotes the expression of *mir-279* and *Socs36E* to keep Jak/STAT signaling from getting too high \[[@B89-ijms-19-04056],[@B193-ijms-19-04056]\]. Recent studies have shown that a component of a chromatin remodeling complex, encoded by *Brahma*, genetically interacts with *Stat92E*, indicating that epigenetic regulation plays a key role in modulating the transcriptional output of the pathway in motile cells \[[@B96-ijms-19-04056]\], as is the case in *Drosophila* testes stem cells \[[@B142-ijms-19-04056],[@B143-ijms-19-04056],[@B145-ijms-19-04056],[@B194-ijms-19-04056]\].

In border cells, Jak/STAT regulation is also controlled by cellular trafficking mechanisms. Exocytic regulation of Upd release from polar cells requires Snap Receptor (SNARE) components, N-ethylmalemide-Sensitive Factor (NSF) and alpha-Soluble NSF attachment protein (αSNAP), which reset the SNARE complexes to permit vesicle trafficking \[[@B195-ijms-19-04056]\]. Endocytic control regulates turnover of activated receptors, which can downregulate signaling \[[@B61-ijms-19-04056],[@B98-ijms-19-04056],[@B99-ijms-19-04056]\]. Additional regulatory components for Jak/STAT signaling at the molecular and cell biological level are currently under investigation.

6. *Drosophila*-Jak/STAT Regulators Implicated in Human Metastatic Diseases {#sec6-ijms-19-04056}
===========================================================================

The power of *Drosophila* genetics lies in the ability to identify new components of a process in an unbiased way. This strategy has been fruitful in determining many Jak/STAT signaling regulators in the cell types discussed above, as well as in other contexts that are beyond the scope of this review. As is clear, Jak/STAT signaling is functionally and mechanistically conserved between flies and humans, and many regulators are shared between these pathways. However, more regulatory players have been characterized to act on *Drosophila* Jak/STAT signaling but are not yet connected to this pathway in humans. In the following section, we discuss the human homologs of positive and negative *Drosophila* Jak/STAT regulators in cancer progression and metastasis (see [Table 1](#ijms-19-04056-t001){ref-type="table"}). In many cases, the mechanisms by which these regulators result in cancer are unknown. We propose that their known interactions with Jak/STAT signaling in *Drosophila* lays the groundwork to explore similar potential roles in different types of cells and to understand their involvement in cancers better.

6.1. Positive Drosophila Jak/STAT Regulators in Metastasis {#sec6dot1-ijms-19-04056}
----------------------------------------------------------

Beside core components, multiple positive regulators of the *Drosophila* Jak/STAT signaling pathway have human homologs that are implicated in cancer progression, invasiveness, and/or metastasis ([Table 1](#ijms-19-04056-t001){ref-type="table"}). The ovarian protein OCIAD1 is overexpressed in metastatic cancer tissue compared to primary ovarian tumors \[[@B196-ijms-19-04056]\]. Overexpression of OCIAD1 in the presence of lysophosphatidic acid induced cell adhesion to collagen and laminin in human ovarian cancer cell lines. Thus, OCIAD1 is a regulator of ovarian cancer cell migration and metastasis, and its *Drosophila* homolog, Asrij, is a positive regulator of Jak/STAT signaling in hematopoiesis \[[@B197-ijms-19-04056]\]. OCIAD2 is often associated with OCIAD1, and it also can promote STAT3 activation and cell migration in human cell culture \[[@B198-ijms-19-04056]\]. This supports the hypothesis that OCIAD1 may upregulate metastatic potential via Jak/STAT regulation in human ovarian cancer.

Elevated levels of the Pleckstrin homology domain-interacting protein (PHIP) is predictive of distant metastasis and reduced survival in human melanoma \[[@B199-ijms-19-04056]\]. Silencing PHIP in an ovarian cancer cell line reduced invasion into Matrigel by more than one-third, and reduced metastatic potential by about half in a mouse model. Given that the fly homolog of PHIP, BRWD3, is a known positive regulator of Jak/STAT in *Drosophila* \[[@B73-ijms-19-04056]\], Jak/STAT involvement in PHIP-dependent metastasis is worth further investigation.

IGF2BP1 is an mRNA binding factor implicated in multiple cancers \[[@B200-ijms-19-04056]\]. Silencing of the IGF2BP1 gene reduced cell proliferation, migration and invasiveness of a cervical cancer cell line and HeLa cells in wound healing and trans-well migration assays \[[@B201-ijms-19-04056]\]. *MicroRNA 140-5p* targets IGF2BP1 in this tissue. In vitro assays showed that IGF2BP1 downregulation by another microRNA (*miR-150*) reduced migration and invasion of an osteosarcoma cell line \[[@B202-ijms-19-04056]\]. Moreover, *miR-150* suppressed tumor growth in an osteosarcoma xenograft mouse model via repression of IGF2BP1. In both hepatocellular carcinoma and glioblastoma cell lines, downregulating IGF2BP1 via different microRNAs reduces tumor proliferation and invasion potential \[[@B203-ijms-19-04056],[@B204-ijms-19-04056]\]. In patients, high expression of this protein was associated with lung cancer progression \[[@B205-ijms-19-04056]\]. Thus, IGF2BP1 behaves as a pro-metastatic agent, consistent with a predicted role in promoting Jak/STAT activity, like its homolog (Imp) acts in fly testes \[[@B206-ijms-19-04056]\].

PRDX4 is linked to cancer progression in multiple cell types. It is overexpressed in non-small cell lung cancer and prostate cancer \[[@B207-ijms-19-04056],[@B208-ijms-19-04056]\]. Molecularly, it appears to be a thioredoxin peroxidase. The PRDX4 gene and protein are also upregulated in human glioblastoma multiforme (GBM) and mouse models of this disease \[[@B209-ijms-19-04056]\]. In vitro suppression of PRDX4 caused the reduction of GBM stem cell-like proliferation and the prolonged survival in orthotopic transplantation to mouse. The PRDX4 homolog in flies, Jafrac2, promotes hemocyte overgrowth by upregulating Jak/STAT activity \[[@B210-ijms-19-04056]\]. Further investigation is required to determine if PRDX4 has a role in metastasis through Jak/STAT signaling.

The transcription factor CEBPD acts as a pro-metastatic factor in several cancers. CEBPD overexpression increased urothelial cell migration and showed an increase in invasion potential in vitro \[[@B211-ijms-19-04056]\]. Inhibition of MMP2 significantly blocked CEBPD-induced migration and invasion properties. Additionally, lung tumor metastasis was significantly lower when tumor cells were injected into a CEBPD-null mouse compared to a control. However, this suggests an indirect effect of CEBPD in metastasis. Overexpression of CEBPD in lymphatic cells increased cell migration in vitro, and conversely its repression inhibited cell motility. In flies, the CEBPD homolog, Slbo, is a key transcriptional target of activated STAT in border cells \[[@B24-ijms-19-04056]\]; thus, we propose CEBPD may be activated and function analogously to promote migration during tumor metastasis.

6.2. Negative Drosophila Jak/STAT Regulators in Metastasis {#sec6dot2-ijms-19-04056}
----------------------------------------------------------

As is clear, abnormal activation of Jak/STAT can result in tumorigenesis and metastasis. Thus, negative regulators of the pathway could have roles in disease progression as well, especially if they are lost or blocked. As many negative regulators have been characterized in *Drosophila*, these are worthy of attention. The human proteins BPTF, UBAP2, REST, and EYA2 have *Drosophila* counterparts that act to repress Jak/STAT signaling in various cell types ([Table 1](#ijms-19-04056-t001){ref-type="table"}). Though changes in each of these factors are associated with human cancer progression and metastasis, a direct connection to Jak/STAT signaling is less clear.

The nucleosome-remodeling factor BPTF has been shown to be present in various cancers with different metastatic potentials. Examination of patient tumor samples indicated that BPTF is a suppressor of lung cancer metastasis to the brain \[[@B212-ijms-19-04056]\]. In a cultured melanoma cell line, BPTF suppressed proliferative capacity and significantly reduced metastases upon intravenous injection in nude mice \[[@B213-ijms-19-04056]\]. However, in a different melanoma line, increased BPTF expression induced cell proliferation \[[@B214-ijms-19-04056]\]. Consistent with the latter, knockdown of BPTF in lung adenocarcinoma cell lines inhibited cell proliferation and lung cancer growth in mouse models \[[@B215-ijms-19-04056]\]. In hepatocellular carcinoma patients, BPTF was associated with low E-cadherin levels, high tumor numbers, and more vascular invasion \[[@B216-ijms-19-04056]\]. Colorectal cancer patients who had higher BPTF expression tended to have poor survival \[[@B217-ijms-19-04056]\], which suggests BPTF promotes cancer progression. Given the repressive function of its *Drosophila* homolog (E(Bx)) in Jak/STAT signaling, we hypothesize that BPTF could be involved in human cancer metastasis, in part, by suppressing Jak/STAT signaling. However, BPTF can be linked with pro- or anti-metastatic roles, which may mean changes in its expression are indirect, that it has cell type specific effects, or that it may act in human cancer pathogenesis via multiple mechanisms.

UBAP2 contains a ubiquitin-associated domain, so is presumed to function in protein turnover. *UBAP2* was found to be overexpressed at the gene level in samples collected from castration-resistant prostate cancer patients \[[@B218-ijms-19-04056]\]. Additionally, UBAP2 expression was significantly higher in advanced prostate cancer and was even higher in metastatic prostate cancer. In prostate cancer cell lines, reduction of *UBAP2* copy number significantly reduced cell growth. On the other hand, UBAP2 was lowly expressed in hepatocellular carcinoma (HCC) patient samples \[[@B219-ijms-19-04056]\]. In HCC cell lines, knockdown of UBAP2 enhanced invasion, proliferation, and tumor growth in vivo. The *Drosophila* homolog Lig mutates to embryonic lethality, but has mainly been shown to affect Jak/STAT signaling in eye progenitor cell growth \[[@B220-ijms-19-04056]\], suggesting that it participates in cell type-specific regulation. Thus, it seems that UBAP2 might have tissue dependent roles in cancer as well. Whether it acts via regulating Jak/STAT signaling in metastasis is worth further study.

Reduction of another putative Jak/STAT regulator, the transcription factor REST, increased LIN28A expression and tumor growth both in cell culture and in models in vivo \[[@B221-ijms-19-04056]\]. The tumor samples that showed low REST expression also showed local invasion. REST is also a proposed clinical marker for advanced prostate cancer \[[@B222-ijms-19-04056]\]. However, in spite of data suggesting that REST has an anti-proliferative role, there has not yet been demonstration of Jak/STAT signaling involvement in this function. The fly homolog of REST is Pzg, which functions both in steroid hormone signaling and Jak/STAT signaling, in part through modulating nucleosome remodeling \[[@B223-ijms-19-04056]\]. Thus, REST's function in cancer cells may also link to chromatin regulation.

Lastly, the transcription factor EYA2 was shown to be misregulated in a number of cancers. In lung adenocarcinoma patient samples, it was upregulated, and upon its knockdown in cell culture, tumor growth and invasion potential were suppressed \[[@B224-ijms-19-04056]\]. EGFR has been shown to activate EYA2 leading to breast cancer growth, EMT, invasion, and lung metastasis in vitro and in vivo \[[@B225-ijms-19-04056]\]. In contrast, a majority of pancreatic adenocarcinoma patients showed loss of EYA2 in tumor cells \[[@B226-ijms-19-04056]\]. Reduction of EYA2 in pancreatic cancer cell lines increased cell proliferation, and stable EYA2 expression reduced metastasis in mouse xenographs. In *Drosophila*, the corresponding protein Eya activates Apontic, which negatively regulates Jak/STAT signaling in ovarian follicle cells \[[@B193-ijms-19-04056]\], but Eya has multiple other roles in different cell types. Further investigation on EYA2's mode of action and the possible involvement of Jak/STAT signaling in cancer metastasis are interesting areas yet to be understood.

In summary, many of the human homologs of *Drosophila* positive Jak/STAT regulators are shown to be linked to human cancer progression and/or metastasis. Understanding their mode of action in cancer progression via, possibly, Jak/STAT signaling could provide us a new direction towards therapeutic interventions.

7. Outlook {#sec7-ijms-19-04056}
==========

The portrait of Jak/STAT signaling in human cancer metastasis is far from complete, and is obviously very complex. The description we provide here fortifies the idea that further explanation of Jak/STAT regulation in *Drosophila* is warranted and useful for uncovering new genes with roles in human disease. Interestingly, new levels of pathway regulation are becoming apparent in multiple *Drosophila* cell types. These findings suggest that future studies are needed to evaluate further vesicle trafficking regulation and epigenetic control of Jak/STAT activity and target gene expression. Additional drug screening in *Drosophila* is also likely to be very informative. Further studies of the candidates described here and new ones will likely shed light on the regulation of cancer metastasis by Jak/STAT signaling or additional linked pathways.
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![The *Drosophila* Jak/STAT signaling components and the corresponding human homologs and their protein families. Interleukin or cytokine (the Upd family in flies) binds to its signaling receptor (Dome in flies), which activates the associated Jak (fly Hop) and triggers a chain of events. Activated Jak phosphorylates other Jaks and the receptor, creating a binding site for STAT proteins. Recruited STAT proteins (fly STAT92E), are then phosphorylated. The phospho-STATs dimerize and translocate to the nucleus. The STAT DNA binding domain recognizes promoter and enhancer regions of target genes, resulting in their transcriptional activation. The table above the figure lists the core components of the canonical pathway. The table to the right delineates key regulators of the fly Jak/STAT pathway, their respective human homologs, and their protein families. Positive regulators are listed in green font, negative regulators are in red. See text for details.](ijms-19-04056-g001){#ijms-19-04056-f001}
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Roles for *Drosophila* Jak/STAT signaling components and their human homologs in development and cancer metastasis.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Drosophila* Jak/STAT Component                             *Drosophila* Cell Type/Tissue                                                                                              Human Homolog                                                Metastatic Cancer Type
  ----------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------
  Signal Transducer and Activator of Transcription92E\        Brain \[[@B227-ijms-19-04056]\]\                                                                                           Signal Transducer and Activator of Transcription 5b\         Brain Cancer \[[@B234-ijms-19-04056]\]\
  (STAT92E)                                                   Embryo \[[@B3-ijms-19-04056],[@B7-ijms-19-04056]\]\                                                                        (STAT5b)                                                     Breast Cancer \[[@B149-ijms-19-04056],[@B150-ijms-19-04056]\]\
                                                              Eyes \[[@B51-ijms-19-04056],[@B53-ijms-19-04056]\]\                                                                                                                                     Colorectal Cancer \[[@B235-ijms-19-04056],[@B236-ijms-19-04056],[@B237-ijms-19-04056]\]\
                                                              Hindgut \[[@B228-ijms-19-04056],[@B229-ijms-19-04056]\]\                                                                                                                                Melanoma \[[@B238-ijms-19-04056]\]\
                                                              Lymph Glands \[[@B117-ijms-19-04056]\]\                                                                                                                                                 Pancreatic Cancer \[[@B239-ijms-19-04056]\]\
                                                              Ovaries \[[@B24-ijms-19-04056],[@B60-ijms-19-04056],[@B176-ijms-19-04056],[@B177-ijms-19-04056],[@B230-ijms-19-04056]\]\                                                                Prostate Cancer \[[@B163-ijms-19-04056],[@B164-ijms-19-04056]\]\
                                                              Primordial Germ Cells \[[@B231-ijms-19-04056],[@B232-ijms-19-04056],[@B233-ijms-19-04056]\]\                                                                                            
                                                              Testes \[[@B58-ijms-19-04056],[@B59-ijms-19-04056]\]\                                                                                                                                   
                                                              Trachea \[[@B229-ijms-19-04056]\]\                                                                                                                                                      
                                                              Wing Disc \[[@B52-ijms-19-04056]\]                                                                                                                                                      

  Hopscotch (Hop)                                             Brain \[[@B227-ijms-19-04056]\]\                                                                                           Janus Kinase 2 (Jak2)                                        Breast Cancer \[[@B151-ijms-19-04056],[@B153-ijms-19-04056],[@B157-ijms-19-04056]\]\
                                                              Embryo \[[@B7-ijms-19-04056],[@B28-ijms-19-04056]\]\                                                                                                                                    Bone Cancer \[[@B243-ijms-19-04056]\]\
                                                              Eyes \[[@B53-ijms-19-04056],[@B240-ijms-19-04056]\]\                                                                                                                                    Cervical Cancer \[[@B244-ijms-19-04056]\]\
                                                              Haltere Disc \[[@B52-ijms-19-04056]\]\                                                                                                                                                  Colorectal Cancer \[[@B245-ijms-19-04056]\]\
                                                              Hemocytes \[[@B10-ijms-19-04056]\]\                                                                                                                                                     Melanoma \[[@B246-ijms-19-04056]\]\
                                                              Hindgut \[[@B229-ijms-19-04056]\]\                                                                                                                                                      Pancreatic Cancer \[[@B247-ijms-19-04056]\]\
                                                              Leg Disc \[[@B52-ijms-19-04056]\]\                                                                                                                                                      Prostate Cancer \[[@B166-ijms-19-04056],[@B167-ijms-19-04056]\]
                                                              Lymph Glands \[[@B116-ijms-19-04056]\]\                                                                                                                                                 
                                                              Somatic Muscle \[[@B241-ijms-19-04056]\]\                                                                                                                                               
                                                              Ovaries \[[@B23-ijms-19-04056],[@B24-ijms-19-04056],[@B60-ijms-19-04056],[@B177-ijms-19-04056],[@B242-ijms-19-04056]\]\                                                                 
                                                              Trachea \[[@B229-ijms-19-04056]\]\                                                                                                                                                      
                                                              Testes \[[@B58-ijms-19-04056]\]\                                                                                                                                                        
                                                              Wing Disc \[[@B52-ijms-19-04056]\]                                                                                                                                                      

  Domeless (Dome)                                             Brain \[[@B227-ijms-19-04056]\]\                                                                                           Interleukin 6 Receptor (IL-6R)                               Breast Cancer \[[@B154-ijms-19-04056]\]\
                                                              Embryo \[[@B5-ijms-19-04056],[@B6-ijms-19-04056]\]\                                                                                                                                     Bone Cancer \[[@B250-ijms-19-04056]\]\
                                                              Eye \[[@B248-ijms-19-04056]\]\                                                                                                                                                          Colorectal Cancer \[[@B251-ijms-19-04056],[@B252-ijms-19-04056],[@B253-ijms-19-04056]\]\
                                                              Hindgut \[[@B228-ijms-19-04056]\]\                                                                                                                                                      Hepatocellular Carcinoma \[[@B254-ijms-19-04056]\]\
                                                              Lymph Gland \[[@B120-ijms-19-04056],[@B126-ijms-19-04056]\]\                                                                                                                            Ovarian Cancer \[[@B255-ijms-19-04056]\]\
                                                              Ovaries \[[@B23-ijms-19-04056],[@B177-ijms-19-04056],[@B249-ijms-19-04056]\]\                                                                                                           Pancreatic Cancer \[[@B256-ijms-19-04056]\]\
                                                              Trachea \[[@B6-ijms-19-04056]\]\                                                                                                                                                        Prostate Cancer \[[@B165-ijms-19-04056]\]\
                                                              Wing \[[@B52-ijms-19-04056]\]                                                                                                                                                           

  Eye Transformer (Et)                                        Eye \[[@B26-ijms-19-04056]\]\                                                                                              Glycoprotein 130 (GP130)                                     Melanoma \[[@B257-ijms-19-04056]\]\
                                                              Intestines \[[@B26-ijms-19-04056]\]\                                                                                                                                                    Prostate Cancer \[[@B170-ijms-19-04056]\]
                                                              Lymph Gland \[[@B27-ijms-19-04056]\]                                                                                                                                                    

  Ken and Barbie (Ken)                                        Embryo \[[@B258-ijms-19-04056]\]\                                                                                          B Cell CLL/Lymphoma 6 (BCL6)                                 Breast Cancer \[[@B159-ijms-19-04056]\]
                                                              Eyes \[[@B259-ijms-19-04056]\]\                                                                                                                                                         
                                                              Genitalia \[[@B258-ijms-19-04056],[@B259-ijms-19-04056]\]\                                                                                                                              
                                                              Ovaries \[[@B192-ijms-19-04056]\]\                                                                                                                                                      
                                                              Testes \[[@B141-ijms-19-04056]\]                                                                                                                                                        

  Protein Tyrosine Phosphatase 61F (Ptp61F)                   Eyes \[[@B78-ijms-19-04056]\]\                                                                                             Protein Tyrosine Phosphatase 1B (PTP1B)                      Breast Cancer \[[@B160-ijms-19-04056],[@B161-ijms-19-04056]\]\
                                                              Ovaries \[[@B96-ijms-19-04056]\]\                                                                                                                                                       Colorectal Cancer \[[@B260-ijms-19-04056]\]\
                                                              Testes \[[@B141-ijms-19-04056]\]                                                                                                                                                        Esophageal Cancer \[[@B261-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Lung Cancer \[[@B262-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Melanoma \[[@B263-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Ovarian Cancer \[[@B264-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Prostate Cancer \[[@B171-ijms-19-04056]\]

  Protein Inhibitor of Activated STAT (Pias) (Su(var) 2-10)   Eyes \[[@B78-ijms-19-04056]\]\                                                                                             Protein Inhibitor of Activated STAT 1 (PIAS1)                Breast Cancer \[[@B162-ijms-19-04056]\]\
                                                              Hemocytes \[[@B78-ijms-19-04056]\]\                                                                                                                                                     Gastric Cancer \[[@B265-ijms-19-04056]\]\
                                                              Ovaries \[[@B23-ijms-19-04056]\]                                                                                                                                                        Prostate Cancer \[[@B172-ijms-19-04056]\]

  Suppressor of Cytokine Signaling 44A (Socs44A)              Wings \[[@B82-ijms-19-04056]\]                                                                                             Suppressor of Cytokine Signaling 1 (SOCS1)                   Breast Cancer \[[@B156-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Colorectal Cancer \[[@B266-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Hepatocellular Carcinoma \[[@B267-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Melanoma \[[@B268-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Prostate Cancer \[[@B169-ijms-19-04056]\]

  Suppressor of Cytokine Signaling 36E (Socs36E)              Notum \[[@B83-ijms-19-04056]\]\                                                                                            Suppressor of Cytokine Signaling 5 (SOCS5)                   Colorectal Cancer \[[@B269-ijms-19-04056]\]\
                                                              Ovaries \[[@B61-ijms-19-04056],[@B89-ijms-19-04056]\]\                                                                                                                                  Liver Cancer \[[@B270-ijms-19-04056]\]
                                                              Testes \[[@B85-ijms-19-04056],[@B138-ijms-19-04056],[@B139-ijms-19-04056]\]\                                                                                                            
                                                              Wing Disc \[[@B82-ijms-19-04056],[@B83-ijms-19-04056],[@B84-ijms-19-04056],[@B87-ijms-19-04056]\]                                                                                       

  Enhancer of Bithorax (E(Bx))                                Testes \[[@B271-ijms-19-04056]\]                                                                                           Bromodomain PHD Finger Transcription Factor (BPTF)           Brain Cancer \[[@B212-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Colorectal Cancer \[[@B217-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Hepatocellular Carcinoma \[[@B216-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Lung Cancer \[[@B215-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Melanoma \[[@B213-ijms-19-04056],[@B214-ijms-19-04056]\]

  Lingerer (Lig)                                              Eyes \[[@B220-ijms-19-04056]\]\                                                                                            Ubiquitin Associated Protein 2 (UBAP2)                       Hepatocellular Carcinoma \[[@B219-ijms-19-04056]\]\
                                                              Imaginal Discs \[[@B220-ijms-19-04056]\]\                                                                                                                                               Prostate Cancer \[[@B218-ijms-19-04056]\]
                                                              Ovaries \[[@B272-ijms-19-04056]\]                                                                                                                                                       

  Putzig (Pzg)                                                Heart \[[@B273-ijms-19-04056]\]\                                                                                           RE1 Silencing Transcription Factor (REST)                    Breast Cancer \[[@B221-ijms-19-04056]\]\
                                                              Wing Disc \[[@B223-ijms-19-04056]\]                                                                                                                                                     Prostate Cancer \[[@B222-ijms-19-04056]\]\

  Eyes Absent (Eya)                                           Eyes \[[@B274-ijms-19-04056],[@B275-ijms-19-04056],[@B276-ijms-19-04056]\]\                                                Eyes Absent 2 (EYA2)                                         Brain Cancer \[[@B280-ijms-19-04056]\]\
                                                              Salivary Gland \[[@B277-ijms-19-04056]\]\                                                                                                                                               Breast Cancer \[[@B281-ijms-19-04056],[@B282-ijms-19-04056]\]
                                                              Somatic Muscle \[[@B241-ijms-19-04056]\]\                                                                                                                                               
                                                              Ovaries \[[@B193-ijms-19-04056],[@B249-ijms-19-04056],[@B278-ijms-19-04056]\]\                                                                                                          
                                                              Testes \[[@B279-ijms-19-04056]\]                                                                                                                                                        

  Asrij\                                                      Head \[[@B283-ijms-19-04056]\]\                                                                                            Ovarian Cancer Immunoreactive Antigen Domain Containing 1\   Ovarian Cancer \[[@B196-ijms-19-04056]\]
  (Arj)                                                       Hemocyte \[[@B119-ijms-19-04056],[@B120-ijms-19-04056]\]\                                                                  (OCIAD1)                                                     
                                                              Lymph Gland \[[@B197-ijms-19-04056]\]\                                                                                                                                                  
                                                              Trachea \[[@B119-ijms-19-04056]\]                                                                                                                                                       

  Bromodomain and WD Repeat Containing Protein 3 (BRWD3)      Eyes \[[@B284-ijms-19-04056]\]\                                                                                            Pleckstrin Homology Domain Interacting Protein (PHIP)        Melanoma \[[@B199-ijms-19-04056],[@B287-ijms-19-04056]\]
                                                              Heart \[[@B273-ijms-19-04056]\]\                                                                                                                                                        
                                                              Midgut \[[@B285-ijms-19-04056]\]\                                                                                                                                                       
                                                              Salivary Gland \[[@B285-ijms-19-04056]\]\                                                                                                                                               
                                                              Testes \[[@B286-ijms-19-04056]\]                                                                                                                                                        

  IGF-II-mRNA-Binding Protein (Imp)                           Head \[[@B283-ijms-19-04056]\]\                                                                                            Insulin-like Growth Factor II Binding Protein 1 (IGF2BP1)    Bone Cancer \[[@B202-ijms-19-04056]\]\
                                                              Ovaries \[[@B288-ijms-19-04056]\]\                                                                                                                                                      Cervical Cancer \[[@B201-ijms-19-04056]\]\
                                                              Testes \[[@B206-ijms-19-04056],[@B279-ijms-19-04056]\]                                                                                                                                  Hepatocellular Carcinoma \[[@B289-ijms-19-04056],[@B290-ijms-19-04056],[@B291-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Lung Cancer \[[@B205-ijms-19-04056]\]

  Thioredoxin Peroxidase 2 (Jafrac2)                          Head \[[@B283-ijms-19-04056]\]\                                                                                            Peroxiredoxin 4 (PRDX4)                                      Brain Cancer \[[@B209-ijms-19-04056]\]\
                                                              Heart \[[@B273-ijms-19-04056]\]\                                                                                                                                                        Lung Cancer \[[@B207-ijms-19-04056]\]
                                                              Hemolymph \[[@B210-ijms-19-04056]\]                                                                                                                                                     

  Slow Border Cells (Slbo)                                    Ovaries \[[@B292-ijms-19-04056]\]                                                                                          CCAAT Enhancer Binding Protein Delta (CEBPD)                 Lung Cancer \[[@B293-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Nasopharyngeal Carcinoma \[[@B294-ijms-19-04056]\]\
                                                                                                                                                                                                                                                      Urothelial Cancer \[[@B211-ijms-19-04056]\]

  C-Terminal Src Kinase (Csk)                                 Eyes \[[@B295-ijms-19-04056],[@B296-ijms-19-04056]\]\                                                                      C-Terminal Src Kinase (CSK)                                  Colon Cancer \[[@B299-ijms-19-04056],[@B300-ijms-19-04056]\]
                                                              Imaginal Discs \[[@B297-ijms-19-04056]\]\                                                                                                                                               
                                                              Ovaries \[[@B298-ijms-19-04056]\]                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The left side of the table shows canonical *Drosophila* Jak/STAT components and tissues in which they are required or highly expressed. The right side of the table lists the closest human homologs and the types of metastatic tumors in which they are involved.
